Works matching IS 01676997 AND DT 2024 AND VI 42 AND IP 5

Results: 14

Broad-spectrum anti-cancer activity of fused human arginase variants.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 531, doi. 10.1007/s10637-024-01466-8

By:

Prasad, Yenisetti Rajendra;
Anakha, J.;
Jawalekar, Snehal Sainath;
Pande, Abhay H.

Publication type:

Article

Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 575, doi. 10.1007/s10637-024-01472-w

By:

Peng, Liping;
Wu, Zhaoquan;
Sun, Wei;
Wang, Chunjiang

Publication type:

Article

Retraction Note: The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 601, doi. 10.1007/s10637-024-01469-5

By:

De Iuliis, Francesca;
Taglieri, Ludovica;
Salerno, Gerardo;
Giuffrida, Anna;
Milana, Bernardina;
Giantulli, Sabrina;
Carradori, Simone;
Silvestri, Ida;
Scarpa, Susanna

Publication type:

Article

Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 538, doi. 10.1007/s10637-024-01467-7

By:

Tachibana, Yusuke;
Morimoto, Kenji;
Yamada, Tadaaki;
Kawachi, Hayato;
Tamiya, Motohiro;
Negi, Yoshiki;
Goto, Yasuhiro;
Nakao, Akira;
Shiotsu, Shinsuke;
Tanimura, Keiko;
Takeda, Takayuki;
Okada, Asuka;
Harada, Taishi;
Date, Koji;
Chihara, Yusuke;
Hasegawa, Isao;
Tamiya, Nobuyo;
Katayama, Yuki;
Nishioka, Naoya;
Iwasaku, Masahiro

Publication type:

Article

Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer: sitravatinib in advanced RCC and CRPC: Pant et al.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 547, doi. 10.1007/s10637-024-01465-9

By:

Pant, Shubham;
Cho, Byoung Chul;
Kyriakopoulos, Christos E.;
Spira, Alexander;
Tannir, Nizar;
Werner, Theresa L.;
Yan, Xiaohong;
Neuteboom, Saskia;
Chao, Richard;
Goel, Sanjay

Publication type:

Article

Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 510, doi. 10.1007/s10637-024-01464-w

By:

Wu, Zhaoquan;
Sun, Wei;
Wang, Chunjiang

Publication type:

Article

Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 559, doi. 10.1007/s10637-024-01470-y

By:

Mori, Nami;
Tamaki, Nobuharu;
Takaki, Shintaro;
Tsuji, Keiji;
Tada, Toshifumi;
Nakamura, Shinichiro;
Ochi, Hironori;
Mashiba, Toshie;
Doisaki, Masao;
Marusawa, Hiroyuki;
Kobashi, Haruhiko;
Fujii, Hideki;
Ogawa, Chikara;
Nonogi, Michiko;
Arai, Hirotaka;
Uchida, Yasushi;
Urawa, Naohito;
Narita, Ryoichi;
Akahane, Takehiro;
Kondo, Masahiko

Publication type:

Article

Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 566, doi. 10.1007/s10637-024-01463-x

By:

Heath, Elisabeth I.;
Chen, Wei;
Heilbrun, Lance;
Choi, Jae E.;
Dobson, Kimberlee;
Smith, Melanie;
Maj, Tomasz;
Vaishampayan, Ulka;
Kryczek, Ilona;
Zou, Weiping;
Chinnaiyan, Arul M.;
Qiao, Yuanyuan

Publication type:

Article

A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 492, doi. 10.1007/s10637-024-01462-y

By:

Gupta, Pranav;
Chatterjee, Manash;
Kim, Yeonil;
Deschamps, Kathleen;
Lemoine, Lieselotte;
Van Dyck, Kristien;
Matthews, Catherine Zhou;
Rottey, Sylvie;
Stoch, Aubrey;
Lai, Eseng

Publication type:

Article

A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 581, doi. 10.1007/s10637-024-01461-z

By:

Lakhani, Nehal J.;
Burris III, Howard;
Miller Jr., Wilson H.;
Huang, Mo;
Chen, Lin-Chi;
Siu, Lillian L.

Publication type:

Article

Advancements of prodrug technologies for enhanced drug selectivity in pharmacotherapies.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 590, doi. 10.1007/s10637-024-01460-0

By:

Li, Helin;
Zhang, Wenjing;
Meng, Qiu;
Shuai, Qi

Publication type:

Article

A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 481, doi. 10.1007/s10637-024-01458-8

By:

Ghalib, Mohammad H.;
Pulla, Mariano Provencio;
De Miguel Luken, Maria J.;
de Juan, Virginia Calvo;
Chaudhary, Imran;
Hammami, M Bakri;
Vikash, Sindhu;
Maitra, Radhashree;
Martinez, Sara;
Kahatt, Carmen;
Extremera, Sonia;
Fudio, Salvador;
Goel, Sanjay

Publication type:

Article

Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 500, doi. 10.1007/s10637-024-01457-9

By:

Xia, Chunyong;
Liu, Zhijing;
Liu, Jie;
Lin, Li;
Chen, Maohua

Publication type:

Article

Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery.

Published in:

Investigational New Drugs, 2024, v. 42, n. 5, p. 518, doi. 10.1007/s10637-024-01455-x

By:

Silli, Epiphane K.;
Zheng, Zhenjiang;
Zhou, Xintao;
Li, Mengfei;
Tang, Jiali;
Guo, Ruizhe;
Tan, Chunlu;
Wang, Ying

Publication type:

Article